Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3347901 | Diagnostic Microbiology and Infectious Disease | 2009 | 4 Pages |
Abstract
Tumor necrosis factor α antagonists have proven efficacious for a variety of autoimmune-mediated diseases. However, recent data have highlighted the risk of invasive fungal infections with their use. These agents are typically discontinued when infectious complications occur during therapy; however, the immune reconstitution inflammatory syndrome (IRIS) may be seen after drug cessation. We describe the 1st case of IRIS secondary to cryptococcal pneumonia after cessation of adalimumab.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Jose Cadena, George R. Thompson III, Tony T. Ho, Edward Medina, Darrel W. Hughes, Thomas F. Patterson,